A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies

Piotr Rutkowski, Dariusz M. Kowalski, Victor Moreno, Aitana Calvo, Fiona Thistlethwaite, Ruth Plummer, Douglas Steinbach, John Loffredo, Sydney Akapeme, Daniel Jonathan, Vinod Philip, Angela Girvin, Shalaka Hampras, Peter Hellemans, Iurie Bulat

Open source

DOI: 10.1007/s00262-026-04457-1
Published: 2026-06-18
Container: Cancer Immunology, Immunotherapy
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00262-026-04457-1,
  title = {A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies},
  author = {Piotr Rutkowski and Dariusz M. Kowalski and Victor Moreno and Aitana Calvo and Fiona Thistlethwaite and Ruth Plummer and Douglas Steinbach and John Loffredo and Sydney Akapeme and Daniel Jonathan and Vinod Philip and Angela Girvin and Shalaka Hampras and Peter Hellemans and Iurie Bulat},
  year = {2026},
  journal = {Cancer Immunology, Immunotherapy},
  doi = {10.1007/s00262-026-04457-1},
  url = {https://doi.org/10.1007/s00262-026-04457-1}
}

RIS

TY  - JOUR
TI  - A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies
AU  - Piotr Rutkowski
AU  - Dariusz M. Kowalski
AU  - Victor Moreno
AU  - Aitana Calvo
AU  - Fiona Thistlethwaite
AU  - Ruth Plummer
AU  - Douglas Steinbach
AU  - John Loffredo
AU  - Sydney Akapeme
AU  - Daniel Jonathan
AU  - Vinod Philip
AU  - Angela Girvin
AU  - Shalaka Hampras
AU  - Peter Hellemans
AU  - Iurie Bulat
PY  - 2026
JO  - Cancer Immunology, Immunotherapy
DO  - 10.1007/s00262-026-04457-1
UR  - https://doi.org/10.1007/s00262-026-04457-1
ER  -

APA

Rutkowski, P., Kowalski, D. M., Moreno, V., Calvo, A., Thistlethwaite, F., Plummer, R., Steinbach, D., Loffredo, J., Akapeme, S., Jonathan, D., Philip, V., Girvin, A., Hampras, S., Hellemans, P., & Bulat, I. (2026). A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04457-1

Source records

crossref · retrieved 2026-09-26T17:33:04.406Z